Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Efinaconazole 10% solution demonstrated higher effectiveness than vehicle in achieving complete cure (RR (relative risk) 3.54, 95% CI (confidence interval) 2.24 to 5.60; high-quality evidence), clinical cure (RR 3.07, 95% CI 2.08 to 4.53; high-quality evidence), and mycological cure (RR 2.31, 95% CI 1.08 to 4.94; moderate-quality evidence).
• Tavaborole 5% solution likely increases complete cure rates (RR 7.40, 95% CI 2.71 to 20.24; moderate-quality evidence) and mycological cure rates (RR 3.40, 95% CI 2.34 to 4.93; high-quality evidence) compared to vehicle.
• Ciclopirox 8% lacquer may be more effective than vehicle for complete cure (RR 9.29, 95% CI 1.72 to 50.14; low-quality evidence) and likely improves mycological cure (RR 3.15, 95% CI 1.93 to 5.12; moderate-quality evidence).
• Efinaconazole 10% solution showed a slightly higher risk of adverse events, including dermatitis and vesicles (RR 1.10, 95% CI 1.01 to 1.20; high-quality evidence), while tavaborole 5% solution likely increased application site reactions (RR 3.82, 95% CI 1.65 to 8.85; moderate-quality evidence).
• Ciclopirox 8% lacquer and luliconazole 5% solution showed varying adverse event profiles, with ciclopirox potentially leading to application reactions and rashes (RR 1.61, 95% CI 0.89 to 2.92; low-quality evidence) and luliconazole showing minimal difference in adverse events compared to vehicle (RR 1.02, 95% CI 0.90 to 1.16; low-quality evidence).
• There is no population types or subgroups information available in the reviewed studies.